|
Sidec Technologies AB is now following up on the
successful launch of its electron tomography service, for protein
structure and function analysis within drug discovery.
Several new clients and an overwhelming market response made the
company decide to focus entirely on biotech supply. The board has
been added with Dr. Bengt Falk, Mr. Per Sjöberg, Dr. Jon-Sverre
Schanche and Ms. Hedvig Saindrenan, all of whom with long experience
in the biotech supply industry.
Concurrently, The Swedish Industrial Development Fund is
increasing their shares and investing 4 MSEK in the company. Key
personnel at Sidec also participated in the recent issue of new
shares. Earlier this year Sidec established its first client in the
US, and opened a US sales office in San Diego, CA, to better meet
the growing interests overseas.
In successful contract research projects, Sidec has helped
pharmaceutical and biotech companies, in studying e.g.; antibody
epitopes, a membrane bound growth hormone receptor and protein
glycosylation sites. The interest from the market and the number of
such customers is steadily increasing. Therefore Sidec decided to
concentrate exclusively on protein conformation and interaction
analysis for drug discovery even though the company's proprietary
signal reconstruction technology is a general method with several
potential application areas. New board members with relevant
experience have been recruited, and a sharpened strategy
established. The strategy is aimed at creating a one-stop-shop
service for protein structure and function characterization - from
biological systems to chemistry.
The new board members are Dr. Bengt Falk, board member and chairman
of a number of biotech companies in Sweden and Denmark, Mr. Per
Sjöberg, Executive Vice President Marketing and Sales for Gyros AB,
Dr. Jon-Sverre Schanche Vice President R&D, Pyrosequencing and Ms.
Hedvig Saindrenan, Investment Manager, The Swedish Industrial
Development Fund. Also members of the Sidec board are Mr. Stefan
Winberg, Investment manager at The Karolinska Investment Fund, and
Professor Ulf Skoglund, Chief Scientific Officer and founder of
Sidec Technologies AB, Professor of molecular genetics, Karolinska
Institutet. Mr. Lars Henriksson, Controller at The Swedish
Industrial Development Fund and Dr. Johan Raud, Investment Manager
at The Karolinska Investment Fund are deputy members of the board.
For press material contact
Malin Engström
phone: +46 8 508 845 23
e-mail: malin.engstrom@sidectech.se
Gösta Sjöholm, CEO
Phone: +46 8 508 845 21
E-mail: gosta.sjoholm@sidectech.se
About Sidec Technologies AB
Sidec Technologies provides solutions for the rapid studies of
protein conformation and interactions, based on the company's
proprietary 3-D reconstruction technology and electron tomography.
With offices in Stockholm, Sweden and San Diego, California, Sidec
offers contract research services for analysis of membrane bound
proteins as well as studies of proteins in solution, to be used in
drug discovery. Main investors are the Karolinska Investment Fund
and Industrifonden. For more information, please visit
www.sidectech.com
Disclaimer
Statements in this press release that are not strictly historical
are "forward-looking" statements, which involve a high degree of
risk and uncertainty. Such statements are only predictions, and the
actual events or results may differ materially from those projected
in such forward-looking statements.
|
|
